Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas

Clinical Cancer Research

Volumn 21, Issue 24, 2015, Pages 5619-5629

  Tsai, Harrison ^a   Morais, Carlos L ^a   Alshalalfa, Mohammed ^b   Tan, Hsueh Li ^a   Haddad, Zaid ^b   Hicks, Jessica ^a   Gupta, Nilesh ^c   Epstein, Jonathan I ^a   Netto, George J ^a   Isaacs, William B ^a   Luo, Jun ^a   Mehra, Rohit ^d   Vessella, Robert L ^e   Karnes, R Jeffrey ^f   Schaeffer, Edward M ^a   Davicioni, Elai ^b   De Marzo, Angelo M ^a   Lotan, Tamara L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GenomeDx Biosciences Inc   (Canada)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MESSENGER RNA; PROTEIN P16; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CCND1 GENE; CDKN2A GENE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; GENE; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC SMALL CELL CARCINOMA; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RB GENE; SMALL CELL CARCINOMA; ADENOCARCINOMA; ANIMAL; CANCER GRADING; CARCINOMA, SMALL CELL; DISEASE MODEL; GENE EXPRESSION PROFILING; GENETICS; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MORTALITY; MOUSE; PROGNOSIS; PROSTATIC NEOPLASMS; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; BIOMARKERS, TUMOR; CARCINOMA, SMALL CELL; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MICE; NEOPLASM GRADING; NEOPLASM METASTASIS; PROGNOSIS; PROSTATIC NEOPLASMS; RETINOBLASTOMA PROTEIN;

EID: 84954184223     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0744     Document Type: Article

References (50)

1. Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 2012;30:e386-9.
2. Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 2013; 15:1-10.
3. Epstein JI, Netto GN. Biopsy interpretation of the prostate. 2nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2008.
4. Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 2014;38:756-67.
5. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013;19:3621-30.
6. Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. J Urol 1992;147:935-7.
7. Yuan J, Knorr J, Altmannsberger M, Goeckenjan G, Ahr A, Scharl A, et al. Expression of p16 and lack of pRB in primary small cell lung cancer. J Pathol 1999;189:358-62.
8. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012;44:1104-10.
9. Tan HL, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res 2014;20:890-903.
10. Muller H, Lukas J, Schneider A, Warthoe P, Bartek J, Eilers M, et al. CyclinD1 expression is regulated by the retinoblastoma protein. ProcNatl Acad Sci U S A 1994;91:2945-9.
11. Takebayashi T, Higashi H, Sudo H, Ozawa H, Suzuki E, Shirado O, et al. NFkappa B-dependent induction of cyclin D1 by retinoblastoma protein (pRB) family proteins and tumor-derived pRB mutants. J Biol Chem 2003;278:14897-905.
12. MacPherson D, Sage J, Kim T, Ho D, McLaughlin ME, Jacks T. Cell typespecific effects of rb deletion in the murine retina. Genes Dev 2004; 18:1681-94.
13. Mizuarai S, Machida T, Kobayashi T, Komatani H, Itadani H, Kotani H. Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples. Mol Cancer 2011; 10:31.
14. Geradts J, Kratzke RA, Niehans GA, Lincoln CE. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: Correlation with retinoblastoma protein expression. Cancer Res 1995;55:6006-11.
15. Beasley MB, Lantuejoul S, Abbondanzo S, Chu WS, Hasleton PS, Travis WD, et al. The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol 2003;34:136-42.
16. Li AF, Li AC, Tsay SH, Li WY, Liang WY, Chen JY. Alterations in the p16INK4a/cyclin D1/RB pathway in gastrointestinal tract endocrine tumors. Am J Clin Pathol 2008;130:535-42.
17. Andl T, Kahn T, Pfuhl A, Nicola T, Erber R, Conradt C, et al. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 1998;58:5-13.
18. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741-8.
19. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 2012;18:666-77.
20. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011;24:820-8.
21. Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, et al. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer 2012;118:6063-71.
22. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol 2007; 31:1246-55.
23. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15:559-65.
24. Grasso CS,WuYM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239-43.
25. Udager AM, Shi Y, Tomlins SA, Alva A, Siddiqui J, Cao X, et al. Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castrationresistant prostate cancer. Prostate 2014;74:1199-208.
26. Corey E, Vessella RL. Xenograft models of human prostate cancer. In Prostate Cancer: Biology, Genetics and the New Therapeutics. 2nd ed. Leland Chung L, Isaacs W, Simons J, editors. Totowa, NJ: Humana Press; 2007. p. 3-32.
27. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 2013;8:e66855.
28. Piccolo SR, Sun Y, Campbell JD, Lenburg ME, Bild AH, Johnson WE. A single-samplemicroarray normalizationmethod to facilitate personalizedmedicine workflows. Genomics 2012;100:337-44.
29. Darragh TM, Colgan TJ, Thomas Cox J, Heller DS,Henry MR, Luff RD, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: Background and consensus recommendations from the college of American pathologists and the American society for colposcopy and cervical pathology. Int J Gynecol Pathol 2013;32:76-115.
30. Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C,Mitra AP, et al. Validation of a genomic classifier that predictsmetastasis following radical prostatectomy in an at risk patient population. J Urol 2013;190:2047-53.
31. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010;120:4478-92.
32. Zhang X, Coleman I, Brown LG, True LD, Kollath L, Lucas JM, et al. SRRM4 expression and the loss of REST activity may promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer. Clin Cancer Res 2015 Jun 12.[Epub ahead of print].
33. True LD, Buhler K, Quinn J, Williams E, Nelson PS, Clegg N, et al. A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. Am J Pathol 2002;161:705-15.
34. Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, et al. RBpathway disruption in breast cancer: Differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle 2010;9:4153-63.
35. Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the Dtype cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 1994;54:6078-82.
36. Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res 2014;74:1272-83.
37. Haffner MC, De Marzo AM, Yegnasubramanian S, Epstein JI, Carter HB. Diagnostic challenges of clonal heterogeneity in prostate cancer. J Clin Oncol 2014;33:e38-e40.
38. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010;42:668-75.
39. Rajan P, Sudbery IM, Villasevil ME, Mui E, Fleming J, Davis M, et al. Nextgeneration sequencing of advanced prostate cancer treated with androgendeprivation therapy. Eur Urol 2014;66:32-9.
40. Lehmusvaara S, Erkkila T, Urbanucci A, Waltering K, Seppala J, Larjo A, et al. Chemical castration and anti-androgens induce differential gene expression in prostate cancer. J Pathol 2012;227:336-45.
41. Holzbeierlein J, Lai P, LaTulippe E, Smith E, Atagopan J, Zhang L, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-29.
42. Wyatt AW, Mo F, Wang K, McConeghy B, Brahmbhatt S, Jong L, et al. Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biol 2014;15:426.
43. Sharma A, Comstock CE, Knudsen ES, Cao KH, Hess-Wilson JK, Morey LM, et al. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res 2007;67: 6192-203.
44. Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, et al. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. Cell Rep 2015 Jul 29. [Epub ahead of print].
45. Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, et al. Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. Mol Cancer Ther 2012;11:775-83.
46. Chatterjee SJ, George B, Goebell PJ, Alavi-TafreshiM, Shi SR, Fung YK, et al. Hyperphosphorylation of pRb: A mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol 2004;203:762-70.
47. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008; 32:65-71.
48. Di Sant Agnese PA, Cockett AT. The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: A review and future directions in basic research. J Urol 1994;152:1927-31.
49. Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park B, Bieberich CJ, et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 2009;69:603-9.
50. de Leeuw R, Berman-Booty LD, Schiewer MJ, Ciment SJ, Den RB, Dicker AP, et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res 2015;21:795-807.